Does Daxxify have a patent?
Daxxify (daxibotulinumtoxinA-lanm) is a prescription botulinum toxin product, and its underlying drug formulation and related intellectual property have been covered by patents, including those tied to the company’s development and manufacturing approach [1][2].
Who holds the patent(s), and what are they protecting?
The patent protections associated with Daxxify are generally aimed at the product’s specific composition/formulation and related technology rather than just the medical use of botulinum toxin broadly [1][2].
When do patents expire?
Patent expiration depends on the specific patent family and jurisdiction, including filing date, patent term adjustments, and any extensions. Because Daxxify can have multiple patents in force, different patents can expire at different times rather than on a single date [1][2].
How can you check whether a specific Daxxify patent is still active?
To confirm whether a particular patent is currently in force, you typically need to look up the exact patent number (or patent family) in the relevant database (for example, the US Patent and Trademark Office) and then check its status and expiration data [1][2].
Are there any updates like challenges or new exclusivity deals?
Patent status can change over time due to litigation, approvals, and exclusivity or regulatory periods tied to the drug’s approval. Keeping track requires monitoring both patent databases and regulatory exclusivity records for Daxxify [1][2].
Sources:
[1] https://patents.google.com/?q=daxibotulinumtoxinA-lanm
[2] https://www.accessdata.fda.gov/scripts/cder/daf/